Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MPL | P40238 | 5/20 | 0.44 |
| ▸ | GUCY1B2 | O75343 | 13/20 | 0.42 |
| ▸ | GUCY1A2 | P33402 | 13/20 | 0.42 |
| ▸ | GUCY1A1 | Q02108 | 13/20 | 0.42 |
| ▸ | GUCY1B1 | Q02153 | 13/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3234836 | 0.94 | L3MBTL1 (0.44) | L3MBTL1MPLGUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL14952919 | 0.92 | L3MBTL1 (0.48) | L3MBTL1MPLGUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL3234891 | 0.92 | GUCY1B2 (0.48) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL3230163 | 0.87 | GUCY1B2 (0.44) | L3MBTL1GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL3228953 | 0.86 | GUCY1B2 (0.45) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL3227268 | 0.86 | GUCY1B2 (0.48) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL3235323 | 0.86 | PTGDR2 (0.42) | L3MBTL1GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL3229063 | 0.85 | GUCY1B2 (0.45) | L3MBTL1GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL3222758 | 0.85 | L3MBTL1 (0.45) | L3MBTL1MPLGUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL14952900 | 0.84 | L3MBTL1 (0.44) | L3MBTL1MPLGUCY1B2GUCY1A2GUCY1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2594270-A2 | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) | BIP Patents (DE) | 2013-05-22 | — | — | EP | claimed |
| WO-2010015652-A2 | THIAZOLE COMPOUNDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | SMITHKLINE BEECHAM CORPORATION (US) | 2010-02-11 | — | — | WO | claimed |
| EP-2594270-A2 | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) | BIP Patents (DE) | 2013-05-22 | — | — | EP | disclosed |
| WO-2010015652-A2 | THIAZOLE COMPOUNDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | SMITHKLINE BEECHAM CORPORATION (US) | 2010-02-11 | — | — | WO | disclosed |